Kazia Therapeutics Late Wednesday Announced Phase II Clinical Study To Investigate Paxalisib In Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma
Portfolio Pulse from Charles Gross
Kazia Therapeutics (NASDAQ:KZIA) is supporting the University of Sydney in a phase II clinical study to investigate paxalisib in patients with recurrent/progressive IDH-mutant grade 2 and 3 glioma. The study, LUMOS2, will be sponsored by the University of Sydney and coordinated by NHMRC Clinical Trials Centre.
June 08, 2023 | 9:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kazia Therapeutics is supporting a phase II clinical study of paxalisib in patients with recurrent/progressive IDH-mutant grade 2 and 3 glioma, which may positively impact the company's stock.
Kazia Therapeutics is supporting a phase II clinical study of paxalisib, which is a significant step in the development of the drug. If the study yields positive results, it could lead to increased demand for the drug and boost the company's stock. The news is highly relevant to KZIA as it directly involves their product, and it is important for investors as it could impact the company's future growth.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100